Chronic pelvic pain (CPP) is characterised by a persistent discordance between symptom severity and identifiable structural pathology, frequently coexisting with lower urinary tract symptoms (LUTS) and bowel dysfunction. Conventional models that attribute pain primarily to peripheral or lesion-based pathology do not adequately explain this mismatch. Sacral neuromodulation (SNM) has demonstrated consistent efficacy across urinary, bowel, and pain domains; however, its mechanism of action in CPP remains incompletely defined. We hypothesised that SNM does not act as a primary analgesic intervention, but instead restores dysfunctional pelvic neural network activity, with pain relief emerging as a secondary consequence of functional recovery. This study aimed to evaluate this network-based mechanistic framework and its clinical implications.

A structured narrative synthesis was conducted using evidence from international guidelines, systematic reviews, meta-analyses, and prospective and retrospective cohort studies evaluating SNM in CPP and related conditions, including bladder pain syndrome/interstitial cystitis and endometriosis. Outcomes were analysed across multiple domains, including pain, lower urinary tract function, bowel function, quality of life, and treatment durability. Particular emphasis was placed on identifying consistent patterns of response across symptom domains and on the temporal relationship between functional improvement and pain reduction.

Across heterogeneous CPP populations, SNM demonstrates consistent and reproducible multidomain therapeutic effects, with reported success rates ranging from 70–85%. Improvements in pain occur in parallel with restoration of pelvic organ function, including reductions in urinary urgency, frequency, voiding symptoms, and bowel symptoms, alongside improved quality of life. This synchronised response is observed across clinical phenotypes and appears largely independent of underlying structural pathology. Long-term studies demonstrate sustained benefit, including reduced analgesic use and improved functional status.
In endometriosis, persistence of pain despite apparently adequate surgical treatment, combined with responsiveness to SNM, challenges lesion-based models of pain. Similarly, in bladder pain syndrome, the dissociation between symptom severity and cystoscopic findings supports a functional rather than structural basis.

The observed consistency of multidomain improvement suggests that the effects of SNM in CPP are not isolated to pain modulation but reflect restoration of integrated pelvic organ function. The parallel improvement in urinary, bowel, and pain symptoms, together with the lack of correlation between symptom severity and structural pathology, supports a functional rather than lesion-based mechanism. Across conditions such as endometriosis and bladder pain syndrome, these patterns indicate that treatment response is more closely related to underlying neural network integrity than to identifiable anatomical abnormalities. This interpretation provides a mechanistic explanation for the variability reported across studies and reinforces the importance of considering CPP as a disorder of dysregulated pelvic neural networks.

SNM in CPP should be conceptualised as a neuromodulatory intervention that restores dysfunctional pelvic neural networks, with pain relief occurring through restoration of pelvic organ function rather than direct analgesia. This framework challenges the prevailing structure-based paradigm of pelvic pain and supports a shift toward function-oriented, phenotype-driven patient selection. By linking mechanism to clinical response, this model offers a coherent and clinically actionable approach to integrating SNM into the management of complex pelvic pain syndromes and may help explain variability in treatment outcomes across heterogeneous populations.